Erectile Dysfunction and Cardiovascular Events in Diabetic Men: A Meta-analysis of Observational Studies

Tomohide Yamada, Kazuo Hara*, Hitomi Umematsu, Ryo Suzuki, Takashi Kadowaki

Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Abstract

Background: Several studies have shown that erectile dysfunction (ED) influences the risk of cardiovascular events (CV events). However, a meta-analysis of the overall risk of CV events associated with ED in patients with diabetes has not been performed.

Methodology/Principal Findings: We searched MEDLINE and the Cochrane Library for pertinent articles (including references) published between 1951 and April 22, 2012. English language reports of original observational cohort studies and cross-sectional studies were included. Pooled effect estimates were obtained by random effects meta-analysis. A total of 3,791 CV events were reported in 3 cohort studies and 9 cross-sectional studies (covering 22,586 subjects). Across the cohort studies, the overall odds ratio (OR) of diabetic men with ED versus those without ED was 1.74 (95% confidence interval [CI]: 1.34–2.27; P<0.001) for CV events and 1.72 (95% CI: 1.5–1.98; P<0.001) for coronary heart disease (CHD). The funnel plot, Begg’s test, and Egger’s test did not show evidence of publication bias (all P>0.05). Moreover, meta-regression analysis found no relationship between the method used to assess ED (questionnaire or interview), mean age, mean hemoglobin A1c, mean body mass index, or mean duration of diabetes and the risk of CV events or CHD. In the cross-sectional studies, the OR of diabetic men with ED versus those without ED was 3.39 (95% CI: 2.58–4.44; P<0.001) for CV events (N=9), 3.43 (95% CI: 2.46–4.77; P<0.001) for CHD (N=7), and 2.63 (95% CI: 1.41–4.91; P = 0.002) for peripheral vascular disease (N=5).

Conclusion/Significance: ED was associated with an increased risk of CV events in diabetic patients. Prevention and early detection of cardiovascular disease are important in the management of diabetes, especially in view of the rapid increase in its prevalence.

Introduction

Cardiovascular disease (CVD) is the main cause of death in patients with diabetes, so its early detection is extremely important [1]. Erectile dysfunction (ED) is defined as the inability to achieve and maintain an erection for satisfactory sexual performance [2], and men with diabetes have a higher prevalence of ED compared with the general population [3]. Studies performed in various populations have found a frequency of ED ranging from 20% to 90%, depending on the method of assessment [4–6]. It has also been reported that the prevalence of ED increases with age and with the duration and severity of diabetes [7]. Several recent studies have shown that ED is associated with the risk of cardiovascular events (CV events) [8,9], and have generally found a positive association, although its magnitude has varied between studies. In addition, two previous meta-analyses [10,11] identified a statistically significant relation between ED and cardiovascular risk. However, a meta-analysis of the overall risk of CV events associated with ED in patients with diabetes, whose CVD risk is far higher than that of persons without diabetes, has not yet been performed. Clarifying the relationship between ED and CV events may facilitate the early detection of high-risk diabetic patients.

Accordingly, we investigated the association of ED with CV events in men with diabetes by performing a meta-analysis.

Methods

Searches

The Medline and Cochrane Library electronic databases (from 1951 until April 22, 2012) were searched using the medical subject headings (MeSH) “Erectile Dysfunction”, “Diabetes”, and “Cardiovascular Disease” to identify observational studies that tested the association between ED and the risk of CV events, coronary heart disease, peripheral vascular disease, or stroke in diabetic men. The reference lists of pertinent articles were also reviewed.

Selection

We performed initial screening of study titles or abstracts, while the second screening was based on full-text review. Cohort studies, case-control studies, and cross-sectional studies evaluating the risk of CV events in relation to ED were considered eligible for inclusion if the following criteria were met: 1) full-text report published in English; 2) reporting of event numbers in each...
exposure category; 3) reporting about the presence/absence of ED; and 4) reporting of CV events. If more than one study covered the same cohort, only the report containing the most comprehensive information on that population was included to avoid analysis of overlapping populations.

Definition of CV events
CV events were defined according to terms in the history (including death from cardiovascular disease) and/or were classified as coronary heart disease (CHD). CHD included coronary artery disease, myocardial infarction, angina pectoris, cardiomyopathy, and other types of ischemic heart disease. Peripheral vascular disease (PVD) included peripheral artery disease, foot ulcers, and amputation of the lower limb.

Assessment of validity
To ascertain the validity of the eligible studies, the quality of each report was appraised with reference to the STROBE statement [12].

Data extraction
Two independent investigators (T.Y. and H.U.) reviewed each report to determine its eligibility and then extracted and tabulated all of the relevant data. Disagreement was resolved by consensus between the two authors. The following information was obtained from each article: first author, year of publication, type of diabetes, country, method of assessing ED, outcomes, follow-up period, total number of patients, age, hemoglobin A1c (HbA1c), body mass index (BMI), duration of diabetes, and variables used for adjustment of analyses. Numerical data reported in the articles were used, and study authors were contacted if necessary to obtain further details. When available, adjusted relative risk estimates and the corresponding 95% confidence intervals (CIs) were extracted and used in the adjusted meta-analysis.

Quantitative synthesis of data
A pooled odds ratio (OR) was calculated to evaluate the association between ED and CV events, CHD, or PVD across the studies by DerSimonian-Laird random effects meta-analysis. The equivalence of ORs between cohort studies and cross-sectional studies was assessed by z-statistic tests. Meta-regression analyses were performed to explore sources of heterogeneity. Variables such as the method used for assessment of ED (International Index of Erectile Function (IIEF) questionnaire or interview), mean age, mean HbA1c, mean BMI, and mean duration of diabetes were examined to detect any significant influence on the risk of CV events and CHD. Moreover, pooled ORs adjusted for possible confounders and their 95% CIs were calculated for the risk of CV events in the cohort studies by the random-effect model weighted with inverse variance. The Cochran $\chi^2$ test and the I-squared test were used to evaluate heterogeneity among studies, with a threshold value of $p = 0.10$ being considered significant [13]. Publication bias was evaluated by creating a funnel plot of each study's effect size versus the SE. Funnel plot asymmetry was assessed by Begg’s test and Egger’s test. Then trim-and-fill computation was used to estimate the influence of publication bias [14]. All statistical analyses were performed with Stata 11.0 software (StataCorp, College Station, TX). Results are expressed as the mean with 95% CI, unless otherwise indicated. Except for tests of heterogeneity, a P value of less than 0.05 was considered significant. All procedures were performed in accordance with the guideline for the meta-analysis of observational studies in epidemiology [15] and the PRISMA statement [16].

Results
Search results
Figure 1 shows a flow diagram of study selection. We identified a total of 754 citations by the two database searches. Of these citations, 718 were excluded by reviewing the title and abstract, leaving 36 studies for further evaluation. Twenty-four of these 36 studies were excluded after full-text evaluation. Most of the excluded studies did not contain pertinent data, while 1 was excluded because of multiple publications. One report [17] was included after we obtained the event numbers used in the original calculations from its author. A total of 12 studies [7,17–27] that covered 22,586 patients eventually fulfilled our inclusion criteria and were used in this meta-analysis.

Study characteristics
The 12 investigations [7,17–27] included in this meta-analysis consisted of 3 cohort studies [17–19] and 9 cross-sectional studies [7,20–27]. Table 1 shows their characteristics. There was moderate heterogeneity of study design, the type of diabetes, and the method used for assessment of ED. The studies were published between 1996 and 2011. Eight studies [17–19,22,24–27] only analyzed type 2 diabetic patients, 1 [20] was only performed on type 1 diabetic patients, and 3 [7,21,23] covered both types of diabetes. Six studies [19,21,22,24,26,27] were conducted in Europe, 2 [18,23] in Asia, 2 [7,23] in the Middle East, 1 [20] in the USA, and 1 [17] in multiple countries. All 12 studies reported CV events, while 10 [7,17–19,21,23–27] reported on CHD, 6 [19,20,22,23,25,27] reported on PVD. For the 3 cohort studies [17–19], the mean follow-up period ranged from 3.9 to 5.0 years. The size of the study population ranged from 154 to 9,752 patients (mean: 1,882 patients). The age, HbA1c, BMI, and duration of diabetes were largely in the range between 50–60 years, 7.0–8.0%, 25–28 kg/m2, and 5.0–10.0 years, respectively. The definition and method of assessing ED varied across the studies, with 7 [7,19,23–27] studies being based on the IIEF questionnaire and 5 [17,18,20–22] studies using interview (e.g., asking patients whether they had ED).

Most of the studies at least used the age and duration of diabetes for adjustment (similar to the cohort studies), but the number of variables differed significantly among the studies.

Only 2 reports on cross-sectional studies [24,25] explicitly mentioned the limitations inherent in a cross-sectional design (it cannot explain causality), the possible biases of the study, or the influence of confounders on the results. The other reports on cross-
| First author, year | Type of diabetes | Country | Assessment of ED | Outcomes | Follow-up (yrs) | Number of all patients | Age (yrs) | HbA1c (%) | BMI (kg/m²) | Duration of diabetes (yrs) |
|--------------------|-----------------|---------|-----------------|----------|----------------|------------------------|----------|-----------|------------|--------------------------|
| Ma, 2008\(^a\) [18] | Type 2          | Hong Kong (China) | Interview | CV events, CHD | 4.0 | 2306 | 54.2 | 7.8 | 25.0 | 5.9 |
| Gazzaruso, 2008\(^b\) [19] | Type 2          | Italy | IIEF-5 questionnaire | CV events, CHD, PVD | 3.9 | 291 | 54.8 | 7.3 | 27.5 | 8.2 |
| Batty, 2010\(^c\) [17] | Type 2          | Multiple countries | Interview | CV events, CHD | 5.0 | 6304 | 65.9 | 7.5 | 28.0 | 8.0 |
| Klein, 1996\(^d\) [20] | Type 1          | USA | Interview | CV events, PVD | - | 359 | 37.6 | 10.0 | 25.7 | 22.5 |
| Fedele, 2000\(^e\) [21] | Type 1 and Type 2 | Italy | Interview | CV events, CHD | - | 9752 | 20-69 | NA | NA | NA |
| Kalter-Leibovici, 2005\(^f\) [7] | Undefined | Israel | IIEF-15 questionnaire | CV events, CHD | - | 1040 | 57.0 | 7.7 | 28.5 | 8.0 |
| Berardis, 2005\(^g\) [22] | Type 2          | Italy | Interview | CV events, PVD | - | 1264 | 61.3 | 7.0 | 27.4 | 10.1 |
| Shiri, 2006\(^h\) [23] | Undefined | Iran | IIEF-5 questionnaire | CV events, CHD, PVD | - | 312 | 55.2 | NA | NA | 7.6 |
| Gazzaruso, 2006\(^i\) [24] | Type 2          | Italy | IIEF-5 questionnaire | CV events, CHD | - | 198 | 57.8 | 7.5 | 26.3 | 7.5 |
| Yu, 2010\(^j\) [25] | Type 2          | Hong Kong (China) | IIEF-5 questionnaire | CV events, CHD, PVD | - | 313 | 56.1 | 7.6 | 26.0 | 9.3 |
| Gazzaruso, 2011\(^k\) [26] | Type 2          | Italy | IIEF-5 questionnaire | CV events, CHD | - | 293 | 56.6 | 7.8 | 27.0 | 0 |
| Malpartida, 2011\(^l\) [27] | Type 2          | Spain | IIEF-15 questionnaire | CV events, CHD, PVD | - | 154 | 55.9 | 6.7 | 30.2 | 5 |

BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CV events, cardiovascular events; CHD, coronary heart disease; PVD, peripheral vascular disease; IIEF, International Index of Erectile Function.
\(^a\)Adjusted for age, duration of diabetes, albuminuria, and use of antihypertensive medications.
\(^b\)Adjusted for age, duration of diabetes, hypertension, family history of CHD, smoking, microalbuminuria, HbA1c, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and autonomic dysfunction.
\(^c\)Adjusted for age, BMI, use of metformin or beta-blockers, history of macrovascular or microvascular disease, duration of diabetes, smoking, alcohol intake, physical activity, HbA1c, creatinine, total cholesterol, high-density lipoprotein cholesterol, resting heart rate, blood pressure, and education.
\(^d\)Adjusted for age, duration of diabetes, and HbA1c.
\(^e\)Adjusted for age and duration of diabetes.
\(^f\)Adjusted for age, diabetes duration, HbA1c, microvascular disease, diuretic therapy, work-related and leisure-time physical activity, and alcohol consumption.
\(^g\)Not adjusted.
\(^h\)Adjusted for age, education, type and duration of diabetes, pulmonary disease, depression, fruit intake, smoking, drugs and substance abuse, microalbuminuria, and HbA1c.
\(^i\)Adjusted for age, duration of diabetes, hypertension, family history of coronary artery disease, smoking, microalbuminuria, HbA1c, BMI, cholesterol, triglycerides, LDL, and HDL.
\(^j\)Adjusted for age, duration of diabetes, HbA1c, insulin therapy, hypertension, dyslipidemia, log albumin/creatinine ratio, retinopathy, chronic kidney disease, and cerebrovascular disease.
\(^k\)Adjusted for HbA1c, BMI, cholesterol, triglycerides, LDL, HDL, hypertension, dyslipidemia, family history of coronary artery disease, smoking, microalbuminuria/macroalbuminuria, pharmacologic treatment, and autonomic dysfunction.
\(^l\)Adjusted for age and duration of diabetes.

doi:10.1371/journal.pone.0043673.t001
sectional studies lacked this type of statement. In contrast, confounders were satisfactorily adjusted and limitations were fully described in the reports on the 3 cohort studies [17–19].

Quantitative data synthesis (meta-analysis)

A total of 3,791 CV events were reported in the 3 cohort studies and 9 cross-sectional studies covering a total of 22,586 subjects, including 2,229 events in 9,480 subjects with ED and 1,562 events in 13,106 subjects without ED. None of the studies revealed a lower risk of CV events in patients with ED.

Across the cohort studies, the overall odds ratio (OR) for diabetic men with ED versus those without ED was 1.74 (95% confidence interval [CI]: 1.34–2.27; P < 0.001; P for heterogeneity = 0.15; I-squared = 48%) for CV events and 1.72 (95% CI: 1.5–1.98; P < 0.001; P for heterogeneity = 0.54; I-squared 0%) for CHD (Fig. 2). Substantial heterogeneity was not observed.

Across the cross-sectional studies, the OR for diabetic men with ED versus those without ED was 3.39 (95% CI: 2.58–4.44; P < 0.001; P for heterogeneity = 0.014; I-squared = 58%) for CV events (N = 9), 3.43 (95% CI: 2.46–4.77; P < 0.001; P for heterogeneity = 0.07; I-squared = 49%) for CHD (N = 7), and 2.63 (95% CI: 1.41–4.91; P = 0.002; P for heterogeneity = 0.04; I-squared = 60%) for PVD (N = 5) (Fig. 3).

The difference of ORs for CV events and CHD between the cohort studies and cross-sectional studies was statistically significant (both P < 0.01) according to the z-statistics test.

Meta-regression analysis

We performed meta-regression analysis separately for the 3 cohort studies and the 9 cross-sectional studies.

Adjusted meta-analysis

The relative risk (RR) of CV events in the 3 cohort studies was adjusted for potential confounders. Meta-analysis performed with
these adjusted RRs showed that the presence of ED still predicted CV events, with an RR of 1.57 (95% CI: 1.04–2.36; P = 0.03; P for heterogeneity = 0.001; I-squared = 91%)

**Publication bias**
The funnel plot did not show an asymmetric pattern, and both Begg’s test and Egger’s test revealed no significant publication bias.

---

**Figure 3.** Pooled odds ratios for the risk of cardiovascular events, coronary heart disease, and peripheral vascular disease in diabetic men (cross-sectional studies).

doi:10.1371/journal.pone.0043673.g003
CVD screening in asymptomatic diabetic patients

Mechanism of the relation between ED and CVD

(Begg’s test, \( P = 0.12 \) and Egger’s test, \( P = 0.10 \) for CV events; Begg’s test, \( P = 0.12 \) and Egger’s test, \( P = 0.10 \) for CHD).

Trim-and-fill computation showed that the identified bias did not interfere with interpretation of the results (OR: 1.53 (95% CI: 1.21–1.94), \( P < 0.001 \) for CV events; OR: 1.68 (95% CI: 1.40–1.91), \( P < 0.001 \) for CHD).

Discussion

This meta-analysis of 12 studies from around the world demonstrated that ED is associated with a substantial increase in the risk of CV events, CHD, and PVD in diabetic men. Our findings have implications for the management of diabetes, especially in view of the rapid increase in the prevalence of this disease.

Diabetic men with ED suffer a significant decline in quality-of-life measures [22], but their symptoms may remain unnoticed because many physicians do not inquire about sexual health. It has been reported that the majority of men with diabetes and ED have never been asked about sexual function by their physicians, and therefore do not receive treatment for ED [3]. Our findings suggest that, as already reported [28], ED could be a marker of silent CVD and that silent CVD should be excluded before starting to treat ED.

There have been two previous meta-analyses of the relationship between ED and CVD [10,11], but they were not limited to diabetic patients. The combined RR from both meta-analyses was about 1.5 (1.48 [10] and 1.47 [11]) for CVD. In the present meta-analysis, the estimated RR was a high 1.74. Therefore, it seems that the risk of CVD in men with type 2 diabetes and ED is equivalent or higher than that for non-diabetic men with ED.

Mechanism of the relation between ED and CVD

A normal erection is achieved by an increase of parasympathetic activity and a reduction of sympathetic activity [29]. Several mechanisms to explain the association between ED and CVD have been postulated. One is the “artery size hypothesis” [30]. Atherosclerosis affects all major vascular beds to a similar extent, but the penile arteries have a smaller diameter than the coronary arteries (1–2 mm vs. 3–4 mm) and thus are affected earlier by accumulation of atherosclerotic plaque, so that the onset of ED may precede vascular events in the heart. Another possible explanation is that endothelial dysfunction may be a shared etiologic factor for both diseases [31]. Endothelial dysfunction without atherosclerotic narrowing of the penile arteries is more likely to cause ED than it would be to cause angina if the coronary arteries were similarly affected [32]. There may also be smooth muscle dysfunction as well as endothelial dysfunction in patients with ED, which could occur before onset of systemic vascular disease [33]. Moreover, ED is a major clinical manifestation of diabetic autonomic neuropathy. Autonomic neuropathy impairs cholinergic activation of the erectile process and interferes with autonomic pelvic nerve stimulation and/or corporal nerve release of endogenous neurotransmitters [34].

It should be noted that many of the patients analyzed in our study had type 2 diabetes. There may be differences between type 1 and type 2 diabetes with regard to the relationship of ED and CVD, such as a difference in the age of onset or the prevalence of concomitant medical conditions that are also risk factors for cardiovascular disease, including hypertension and dyslipidemia.

CVD screening in asymptomatic diabetic patients

Recently, there have been many reports about the usefulness of CVD screening in asymptomatic diabetic patients. Type 2 diabetes is associated with an elevated risk of coronary artery disease, but patients are often asymptomatic [35], and the usefulness of screening this population is yet to be elucidated. It has been reported that the incidence of coronary artery disease was not significantly reduced when screening by myocardial scintigraphy was conducted in asymptomatic diabetic patients [36], and it was also reported that coronary CT screening of asymptomatic patients without a history of coronary artery disease was not effective for preventing major cardiovascular events [37].

On the other hand, taking a detailed history was reported to be effective for predicting cardiovascular events in high-risk outpatient [38], while systematic assessment of the family history is useful for evaluating cardiovascular risk [39]. Therefore, regardless of the method employed, screening can be recommended for patients who are considered to have a high risk of cardiovascular events based on their history or clinical findings. The method employed should be practicable in terms of its advantages/disadvantages and cost performance, and patients should be evaluated for eligibility before screening. We consider that taking a history of sexual function, hypertension, and dyslipidemia, as well as a family history of CVD, is helpful for assessing the risk of coronary heart disease.

Limitations

The present analysis had several limitations. First, there is a possibility that relevant research papers were missed (e.g., those not written in English), resulting in selection bias. Second, substantial heterogeneity was observed among the studies, which suggested that the different study categories (cohort or cross-sectional) contributed to this heterogeneity to some extent. Although substantial heterogeneity led to a wide range of plausible risk estimates, we found no evidence to suggest that ED is associated with a lower risk of CV events. The present findings may also reflect the differing epidemiological characteristics of the patient populations included in our meta-analysis. Although CVD confounders did not explain the heterogeneity according to meta-regression analysis, it must be remembered that it is impossible to avoid the influence of measured (and unmeasured) confounders (such as age, obesity, dyslipidemia, alcohol, exercise, endocrine disorders, and ejaculatory dysfunction) in observational studies.

Moreover, although our meta-analysis of the cohort studies and cross-sectional studies revealed a significant difference of the ORs for CV events and CHD, this difference may have been influenced by the limitations inherent in cross-sectional studies and the biases of the studies we analyzed.

Third, there was limited information about the use of medications such as antidepressants, beta-blockers, diuretics, phosphodiesterase inhibitors, testosterone, and antihypertensive agents that may have contributed to ED. Fourth, the method used for assessment of ED varied between studies. The IIEF questionnaire has been adopted as the gold standard when assessing the efficacy of treatment for ED [40]. It provides information about the severity of ED and allows dose-response effects to be examined. Conversely, other methods such as interviewing the subject have a higher likelihood of misclassification bias that could lead to underestimation of the strength of the association, since it is often considered shameful to admit to the existence of ED. However, meta-regression analysis did not identify a significant difference between studies based on the IIEF questionnaire and those based on interview.

Even with these limitations, observational studies can provide useful evidence regarding the potential influence of ED on CV events and the overall pooled estimates were robust. Moreover, there are both clinical and biochemical evidence supporting a
Conclusions

The presence of ED was associated with an increased risk of CV events in diabetic men. Prevention and early detection of CVD are important in the management of diabetes, especially in view of the rapid increase in its prevalence.

References

1. Gu k, Cowie CC, Harris MI (1999) Diabetes and decline in heart disease mortality in US adults. JAMA 281: 1291–1297.
2. NIH Consensus Conference (1993) Impotence. NIH Consensus Development Panel on Impotence. JAMA 270: 83–90.
3. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS (2004) Prevalence of erectile dysfunction among 7,689 patients with diabetes or hypertension, or both. Urology 64: 1196-1201.
4. Cho NH, Ahn CW, Park JY, Ahn TY, Lee HW, et al. (2006) Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. Diabetes Med 23: 198-203.
5. Kromhout JH, Sefet AD, Madhun ZT, Aron DC (2000) Sexual function in men with diabetes type 2: association with glycemic control. J Urol 163: 788-791.
6. Sasaki H, Yamazaki H, Ogawa K, Nonao K, Kawamori R, et al. (2005) Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract 70: 81-88.
7. Kalter-Leibovici O, Wainstein J, Ziv A, Harman-Boehm I, Murad H, et al. (2005) Israel Diabetes Research Group (IDRG) Investigators Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care 28: 1759–1774.
8. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, et al. (2005) Erectile dysfunction and subsequent cardiovascular disease. JAMA 294: 2996–3002.
9. Frantzen J, Speel TG, Kiemeney LA, Meuleman EF (2006) Cardiovascular risk among men seeking help for erectile dysfunction. Ann Epidemiol 16: 85–90.
10. Dong JY, Zhang YH, Qin LQ (2011) Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 58: 1378–1385.
11. Guo W, Liao C, Zou Y, Li F, Li T, et al. (2010) Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J Sex Med 7: 2805-2816.
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61: 348–355.
13. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
14. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455-463.
15. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012.
16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151: W65–W94.
17. Ratty GD, Li Q, Czernichow S, Neal B, Zoungas S, et al. (2010) Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. J Am Coll Cardiol 56: 1908-1919.
18. Ma RC, So TW, Yang X, Yu LW, Kong AP, et al. (2008) Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 51: 2045-2050.
19. Gazzaruso C, Solerte SB, Pujia A, Coppola A, Vezzoli M, et al. (2008) Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 51: 2010-2014.
20. Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ (1996) Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 19: 135–141.
21. Federle D, Bortolotti A, Coscelli C, Santusano F, Chaterneau L, et al. (2000) Erectile dysfunction in type 1 and type 2 diabetes in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol 29: 524–531.
22. De Berardis G, Pellegrini F, Franciosi M, Belliglione M, Di Nardo B, et al. (2005) Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. Diabetes Care 28: 2657–2663.
23. Shi R, Aruasi M, Fahah Hasani K (2006) Association between comorbidity and erectile dysfunction in patients with diabetes. Int J Impot Res 18: 348–353.
24. Gazzaruso C, Pujia A, Solerte SB, Amici ED, Emanuele E, et al. (2006) Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. Int J Impot Res 18: 311–315.
25. Yu LW, Kong AP, Tong PC, Tam C, Ko GT, et al. (2010) Evaluation of erectile dysfunction and associated cardiovascular risk using structured questionnaires in Chinese type 2 diabetic men. Int J Androl 33: 853–860.
26. Gazzaruso C, Coppola A, Montanini T, Valentini C, Garazzani A, et al. (2011) Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 46: 273–279.
27. García-Malpàrriz K, Márrom R, Jover A, Gómez-Martínez MJ, Sola-Impiuco E, et al. (2011) Relationship between erectile dysfunction and silent myocardial ischemia in type 2 diabetic patients with no known macrovascular complications. J Sex Med 8: 2606–2616.
28. Gazzaruso C, Gori-Fantacci S, De Amici E, Bertone G, Falcose C, et al. (2004) Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 110(1):22–26.
29. Andersson KE, Wagner G (1995). Physiology of penile erection. Physiol Rev 75: 191–236.
30. Montorsi P, Ravagnani PM, Gali S, Rotatori F, Briganti A, et al. (2005) The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 96: 19M–21M.
31. Kirby M, Jackson G, Simonsen U (2005) Endothelial dysfunction links erectile dysfunction to heart disease. J Clin Pract 59: 225–229.
32. Vlachopoulos C, Iakimidis N, Terentes-Prinotis D, Stefanadis C (2008) The triad: erectile dysfunction-endothelial dysfunction-cardiovascular disease. Curr Pharm Des 14: 3700–3714.
33. Kaiser DK, Billups K, Mason E, Wetterling R, Lundberg JL, et al. (2004) Impaired brachial artery endothelium-dependent and-independent vasodilatation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 43: 179–184.
34. Vinik AI, Maser RE, Mitchell BD, Freeman R (2003) Diabetic autonomic neuropathy. Diabetes Care 26(5):1553–1579.
35. Wackers EF, Young LH, Inzucchi SE, Chuyan DA, Davey JA, et al. (2004) Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 27:1054–1061.
36. Young LH, Wackers EF, Chuyan DA, Davey JA, Barrett EF, et al. (2009) Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 301:1547-1553.
37. McEvoy JW, Blaha MJ, Nasir K, Yoon YE, Choi EK, et al. (2011) Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population. Arch Intern Med 171:1260-1269.
38. Bhattacharj D, Eagle KA, Olmran EM, Hirsch AT, Goto S, et al. (2010) Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304:1350–1357.
39. Qireshi N, Armstrong S, Dhiman P, South S, Pildesman J, et al. (2012) Effect of adding systemic family history enquiry to cardiovascular disease risk assessment in primary care: a matched-pair, cluster randomized trial. Ann Intern Med 156:253–262.
40. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, et al. (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49: 822–830.

Supporting Information

Checklist S1 PRISMA Checklist. (DOC)

Author Contributions

Conceived and designed the experiments: TY. Performed the experiments: TY HU. Analyzed the data: TY. Contributed reagents/materials/analysis tools: TY. Wrote the paper: TY. Reviewed/edited the manuscript: TY HU. KR R8 TK.